I think there are many ways to skin a cat. Trial design is not...

I think there are many ways to skin a cat. Trial design is not that hard when you’ve already designed a phase 1 and probably a phase 2, and the whole NH trial is part of the final trial as you are just looking for the differences, and the Ned points are being finalised now.. This is not a company doing one think at a time( deliberate misspell), they are thinging (lol) well down the track because they can….and have or can find the cash. Other companies have had limitiations on their funds , hence delays. Rohan and Alan seem to be across these limitations and are getting in ahead of the curve.. They are already across most of the trial planning . You have to remember we already have a few hundred (or thousand) people clamouring to get this drug…they can see… the sense…)And the company $ to pay for some things in advance (like production….it is just basic packaging given it goes to hospitals for injection not pharmacies) given the confidence the PYC team exude. if Rohan thinks end of 26 is possible i would give him some kudos having got this far. maybe some slippage but not too long as these people are losing their sight….and the longer they wait…..

As for blinded, yes, phase 2 is blinded. But there are differences between continents that may alter the timelines re unblinding. Any trial can be unblinded if the results are good enough….that I do know. And just maybe they will be that good. This looks like a cure to me, not a treatment, and then thats another game changer. And just wait til we have 4 such drugs across 3 organs in the clinic and hence a platform of significance….careful what you wish for….. might not be long if you read between all the lines.